Stocks · News reference
BTIG Lowers Price Target for Acumen Pharmaceuticals Following Clinical Trial Results
Following the discontinuation of Acumen Pharmaceuticals' lead drug candidate, BTIG maintained a Buy rating on the stock while significantly reducing its price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results
U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.
Acumen Pharmaceuticals to Stop Sabirnetug Development in Alzheimer's After Phase 2 Trial Failure
Acumen Pharmaceuticals is discontinuing the development of its lead clinical candidate, sabirnetug (ACU193), following the failure of a Phase 2 clinical trial to meet its primary endpoint.
8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)
Filed: 2026-10-30 AccNo: 0001628280-26-068425 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash reserves of $78.6 million expected to support operations into early 2027. The company is preparing for November 2026 topline results from its Phase 2 ALTITUDE-AD trial testing sabirnetug for early Alzheimer's disease, with 542 participants enrolled. Management expects a 30% slowing of cognitive decline on the iADRS scale as the clinical success benchmark and anticipates low double-digit ARIA-E safety rates. The company is also advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027.